• Login
    View Item 
    •   Research Bank Home
    • Study Areas
    • Health Sciences
    • Health Sciences Conference Papers
    • View Item
    •   Research Bank Home
    • Study Areas
    • Health Sciences
    • Health Sciences Conference Papers
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers : positive impacts of the Lu177- PSMA treatment in the advanced stage of prostate cancer

    Vyas, Madhusudan; Fagan, Jessica; Shaikh, Shamim

    Thumbnail
    Share
    View fulltext online
    Vyas, M. (2019).pdf (1.560Mb)
    Date
    2019-08-31
    Citation:
    Vyas, M., Fagan, J., & Shaikh, S. (2019, September). A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers: Positive impacts of the Lu177- PSMA Treatment in the advanced stage of Prostate cancer. Paper presented at the NZIMRT/ANZSNM-2019, Rotorua, New Zealand.
    Permanent link to Research Bank record:
    https://hdl.handle.net/10652/4714
    Abstract
    Objective To evaluate the impact/effects of Lutetium-177-PSMA based treatment in improving the quality of life in patients with advanced stage of prostate cancer (mCRPC) Methodology Epidemiology (Global data) Epidemiology (NZ Data) Diagnosis and staging Treatment plan Metastatic disease(mCRPC) Metastatic disease(mCRPC) Metastatic disease(mCRPC) treatment algorithm Metastatic disease(mCRPC) treatment review of literature Prostate specific membrane antigen (PSMA) and mCRPC Various Prostate specific membrane antigen (PSMA) ligands and radionuclides suitable for labelling Lu-177 PSMA based Metastatic disease(mCRPC) treatment review of literature Lu-177-PSMA Treatment outcomes Lu-177 based therapeutic radiopharmaceuticals based treatment outcomes Physiological outcomes of the treatment, at our clinical site QoL, Pain and PSA levels; relative comparison PSA response and QoLoutcomes to Lu-177-PSMA, at our clinical site Third line treatment v/s Lu-177-PSMA Third line treatment v/s Lu-177-PSMA;Feedback from patients Conclusion Reference
    Keywords:
    cancer patients, prostate cancer, theranostics, radionuclide therapy, Lu-177, Lutetium-177, Neuroendocrine tumours (NETs), New Zealand, metastatic castration-resistant prostate cancer (mCRPC), mCRPC
    ANZSRC Field of Research:
    1112 Oncology and Carcinogenesis, 110313 Nuclear Medicine
    Copyright Holder:
    Authors
    Rights:
    This digital work is protected by copyright. It may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use: Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person. You will recognise the author's and publishers rights and give due acknowledgement where appropriate.
    Metadata
    Show detailed record
    This item appears in
    • Health Sciences Conference Papers [13]

    Library home
    Send Feedback
    Research publications
    Unitec
    Moodle
    © Unitec Institute of Technology, Private Bag 92025, Victoria Street West, Auckland 1142
     

     

    Usage

    Downloads, last 12 months
    128
     
     

    Usage Statistics

    For this itemFor the Research Bank

    Share

    About

    About Research BankResearch at UnitecContact us

    Help for authors  

    How to add researchOpen Access GuideVersions Toolkit

    Register for updates  

    LoginRegister

    Browse Research Bank  

    EverywhereAcademic study areasAuthorDateSubjectTitleType of researchSupervisorThis CollectionAuthorDateSubjectTitleType of researchSupervisor

    Library home
    Send Feedback
    Research publications
    Unitec
    Moodle
    © Unitec Institute of Technology, Private Bag 92025, Victoria Street West, Auckland 1142